A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase II trial evaluating the efficacy and safety of SHR-A1811 monotherapy or combined with pyrotinib maleate in Stage II-III HER2-positive breast cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 monotherapy or combined with pyrotinib for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety w wieku od 18 do 75 lat
- •Potwierdzony badaniem histologicznym rak piersi HER2-dodatni
- •Pacjentki, które nie otrzymały wcześniej leczenia, ze stanem II-III
- •Ogólny stan zdrowia oceniony na 0-1 wg ECOG
- •Dobre funkcjonowanie narządów wewnętrznych
✗ Disqualifies
- •Wcześniejsze leczenie przeciwnowotworowe (chemioterapia, radioterapia, terapia molekularna lub hormonalna)
- •Równoczesne otrzymywanie innego leczenia przeciwnowotworowego
- •Rak obustronny, zapalny lub ukryty
- •Zaawansowana postać raka (stan IV)
- •Nowotwór złośliwy w ciągu ostatnich 5 lat
- •Problemy z połykaniem, chroniczna biegunka, niedrożność jelit
- •Uczestnictwo w innych badaniach klinicznych w ciągu ostatnich 4 tygodni
- •Istotne choroby serca lub płuc
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 5, 2024
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Shengjing Hospital affiliated to China Medical University
Shenyang, China
Trial contact
Nan Niu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.